Dr Reddy's Joins Generic Drugmakers Readying Semaglutide Launch
The Hyderabad-based pharmaceutical company is readying 87 countries including core markets such as Canada, Brazil, and India as patents for the drug begin to expire globally, Chief Executive Officer Erez Israeli said Wednesday. A key part of the strategy is targeting countries where Novo Nordisk does not hold patents for semaglutide, he said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Canada slips in mining rankings, but is still home to 2 of world's top 10 most attractive jurisdictions
Saskatchewan and Newfoundland and Labrador are among the top 10 jurisdictions in the world for mining investments, according to an annual report released Tuesday by a Canadian think tank. Finland ranks as the most attractive jurisdiction for mining investment, followed by four states in the United States, according to the Vancouver-based Fraser Institute's Annual Survey of Mining Companies. 'Overall, we see there's significant room for improvement in the policy environment (in Canada),' said Elmira Aliakbari, director of natural resource studies at the Fraser Institute and one of the report's authors. About 350 mining professionals responded to the survey, which was conducted between August and December last year, and they were asked various questions about taxation regimes, environmental protections, labour availability and other topics. About 40 per cent of the respondents worked for exploration companies, 32 per cent for mining companies and the remainder identified as consultants or as other. Last year, four Canadian provinces ranked amongst the world's top 10 jurisdictions, compared to only two this year: Saskatchewan was seventh and Newfoundland and Labrador was eighth. Aliakbari said the decline is mainly due to policy uncertainty, particularly around environmental protections and disputed land claims with indigenous groups. For example, Saskatchewan dropped to seventh on the overall 'Investment Attractiveness Index' after ranking third in 2024 and second in 2023. The report said 'respondents expressed increased concerns over the province's taxation regime, regulatory duplication and inconsistencies, and uncertainty concerning environmental regulations. Ontario dropped in the rankings for the second year in a row, to 15th from 10th last year, because of increased concerns about its taxation regime, labour regulations and political stability. Quebec had an even bigger drop, to 22 from fifth last year, because of increased concerns over taxation, regulatory duplication and its legal system. Aliakbari said British Columbia has 'significant room for improvement' even though it moved up in ranking to 12th from 25th last year. That's because it has geological potential that it isn't fully realizing, she said. Similarly, she said Yukon scores well when assessing its geological potential, but that's not necessarily reflected in its overall investment ranking of 24th because there's a poor perception of its policy environment. 'It means these jurisdictions have failed to capitalize on their mineral potential,' she said. Canadian provinces aren't the only jurisdictions that moved down. Last year, Utah was tops, but it dropped to 11th, with respondents citing increased uncertainty over disputed land claims as well as trade barriers. The Republic of Ireland ranked highest in terms of how mining professionals perceive its policy environment, but a comparatively lower ranking on its geological potential put its overall investment ranking at No. 23. Canada has potential to be a global mining leader, says PwC Mark Carney's import curbs put Canadian steel first Finland ranked second on policy perception, which, when combined with a strong geological potential, placed it first in the overall investment ranking. Since the survey ended, Mark Carney has been elected Canada's prime minister, and the federal government as well as several provinces have passed legislation that could accelerate the timeline and regulatory requirements for major projects such as large mines. Aliakbari said those changes could be reflected in next year's report. For now, she said, respondents, broadly speaking, continued to cite policy uncertainty around environmental protections, disputed land claims and taxation as major barriers to making more mining investments in Canada. 'We see investors continue to cite policy uncertainty as a key deterrent,' Aliakbari said. • Email: gfriedman@
Yahoo
29 minutes ago
- Yahoo
Human Papilloma Virus Testing Market Research Report 2025-2033 Featuring Abbott Laboratories, BioMerieux, Bio-Rad Laboratories, Epigenomics, Siemens Healthineers, Hologic, Qiagen, F. Hoffmann-La Roche
The Human Papillomavirus (HPV) Testing Market is projected to grow from USD 1.52 billion in 2024 to USD 3.62 billion by 2033, at a 10.11% CAGR from 2025. This growth is fueled by increased cervical cancer awareness, robust screening programs, and advancements in diagnostic technologies. HPV, a significant sexually transmitted infection, plays a critical role in cervical and other cancers, highlighting the importance of early detection through testing. Global initiatives, especially in developed nations, have embraced HPV-based screenings, driving demand. However, challenges such as limited access and high technology costs in low-income countries remain. Notable market segments include consumables, immunodiagnostics, and PCR testing. Key regions like the U.S., France, India, and Saudi Arabia see varied growth based on governmental support, awareness, and infrastructure. Human Papilloma Virus Testing Market Dublin, July 29, 2025 (GLOBE NEWSWIRE) -- The "Human Papilloma Virus Testing Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" report has been added to Human papillomavirus (HPV) Testing Market was USD 1.52 billion in 2024 and is expected to reach USD 3.62 billion by 2033, with a CAGR of 10.11% from 2025 to 2033. The growth is due to increasing awareness of cervical cancer, increased screening programs, and technological advancements in diagnostic technologies in global healthcare systems. Internationally, the use of HPV testing is increasing with growing awareness regarding prevention of cervical cancer, government-sponsored screening programs, and WHO's initiative to eliminate cervical cancer as a public health issue. Developed countries have embraced HPV-based screening on a large scale, and developing nations are also adopting it, with the support of global health programs. Its high sensitivity and long-term risk prediction make it a method of choice in contemporary gynecological Driver in the Human Papilloma Virus (HPV) Testing Market Increasing Awareness and Government Screening ProgramsInternational awareness programs and country-level screening programs have increased demand for HPV testing to a large extent. Governments in developed and emerging economies are adopting routine cervical cancer screening guidelines for women aged 30 and older. WHO organizations advocate for HPV testing as a key tool for early detection of cancer. Greater awareness of HPV-associated cancers and immunization also reinforces demand. These efforts account for early diagnosis, prompt intervention, and overall reduction in HPV-associated disease burden, thus driving the market forward. SEP 2024, The United States, Australia, India, and Japan are rolling out a key initiative to fight cervical cancer across the Indo-Pacific, a preventable disease which is a significant health crisis in the region. This initiative is part of larger announcements made during the Quad Leaders Breakthroughs in HPV TestingInnovation in diagnostic methods - like PCR, next-generation sequencing, and self-sampling kits - has revolutionized HPV testing by enhancing accuracy, accessibility, and convenience. Automated platforms, multiplex assays, and liquid-based cytology enable quicker turnaround times and large-scale screening. These technologies are particularly precious in resource-poor settings and enable wider adoption in public health systems. Ongoing R&D spending by diagnostic firms serves to improve test sensitivity and affordability, fueling additional market growth. June 2023, The WHO has prequalified a fourth test for human papillomavirus (HPV). Although most HPV infections will clear on their own, a few of the higher-risk types can cause cervical cancer, so HPV testing is important for cervical cancer Prevalence of HPV-Associated Cancers Growing global incidence of HPV-related cancers, particularly cervical cancer, is a strong market driver. Cervical cancer is the fourth leading female cancer in the world according to the WHO, and the overwhelming majority of cases are caused by high-risk HPV types. Growing cases of cancer have driven the need for early detection strategies, putting HPV testing at the center of preventive medicine. As healthcare professionals and patients strive for surefire diagnostic measures, HPV testing is also becoming a necessity in women's health care. An estimated 47,984 new cases of cancer occur each year in the United States in areas of the body where human papillomavirus (HPV) commonly in the Human Papilloma Virus (HPV) Testing Market Limited Access in Low-Income CountriesIn spite of worldwide awareness, HPV testing is not readily available in low- and middle-income countries because of a lack of healthcare infrastructure and resources. There are few laboratory facilities, skilled professionals, and regular screening programs in most areas. Cultural taboo and sexual stigma also discourage HPV testing participation. This inequality avoids early diagnosis and enhances the risk of cervical cancer at advanced stages. It is essential to overcome these barriers using cost-effective point-of-care diagnostics and education initiatives for equitable market Cost of Sophisticated HPV Testing TechnologiesThe price of advanced HPV testing technologies, including PCR-based platforms and DNA sequencing, can be out of reach for healthcare systems and some patients. As developed nations implement these technologies into regular screening, the affordability gap restricts accessibility in resource-scarce settings. In addition, maintenance costs, quality assurance, and specialized staff requirements contribute to higher operating costs for clinics and laboratories. This cost factor hinders mass screening activities, particularly in developing countries. Key Players Analyzed: Overview, Key Persons, Recent Development & Strategies, Financial Insights Abbott Laboratories BioMerieux SA Bio-Rad Laboratories, Inc. Epigenomics AG Siemens Healthineers AG Hologic Inc Qiagen NV F. Hoffmann-La Roche Ltd Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $1.52 Billion Forecasted Market Value (USD) by 2033 $3.62 Billion Compound Annual Growth Rate 10.1% Regions Covered Global Key Topics Covered: 1. Introduction2. Research Methodology2.1 Data Source2.1.1 Primary Sources2.1.2 Secondary Sources2.2 Research Approach2.2.1 Top-Down Approach2.2.2 Bottom-Up Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Human Papilloma Virus Testing Market5.1 Historical Market Trends5.2 Market Forecast6. Human Papilloma Virus Testing Market Share Analysis6.1 By Application6.2 By Product6.3 By Technology6.4 By End Use6.5 By Countries7. Application7.1 Cervical Cancer Screening7.2 Vaginal Cancer Screening8. Product8.1 Consumables8.2 Instruments8.3 Services9. Technology9.1 Polymerase chain reaction (PCR)9.2 Liquid-based cytology9.3 Immunodiagnostics9.4 Hybrid Capture9.5 Others10. End Use10.1 Hospitals & Clinics10.2 Laboratories10.3 Others11. Countries11.1 North America11.1.1 United States11.1.2 Canada11.2 Europe11.2.1 France11.2.2 Germany11.2.3 Italy11.2.4 Spain11.2.5 United Kingdom11.2.6 Belgium11.2.7 Netherlands11.2.8 Turkey11.3 Asia-Pacific11.3.1 China11.3.2 Japan11.3.3 India11.3.4 South Korea11.3.5 Thailand11.3.6 Malaysia11.3.7 Indonesia11.3.8 Australia11.3.9 New Zealand11.4 Latin America11.4.1 Brazil11.4.2 Mexico11.4.3 Argentina11.5 Middle East & Africa11.5.1 Saudi Arabia11.5.2 UAE11.5.3 South Africa12. Porter's Five Forces Analysis12.1 Bargaining Power of Buyers12.2 Bargaining Power of Suppliers12.3 Degree of Rivalry12.4 Threat of New Entrants12.5 Threat of Substitutes13. SWOT Analysis13.1 Strength13.2 Weakness13.3 Opportunity13.4 Threat 14. Key Players Analysis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Human Papilloma Virus Testing Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
an hour ago
- Yahoo
JPMorgan Holds Overweight on Keurig Dr Pepper Despite Tariff Clouds
Keurig Dr Pepper Inc. (NASDAQ:KDP) is one of the best trade‑war resistant stocks to buy now. On July 17, 2025, JPMorgan's Andrea Teixeira maintained an Overweight rating and nudged the price target down slightly from $39 to $38, reflecting confidence in KDP's resilience amid volatility in coffee input costs and brewing competition. That comes on the heels of strong Q2 2025 earnings reported July 24, where Keurig Dr Pepper posted revenue of $4.16 billion (+6.1%), slightly above expectations, and adjusted EPS of $0.49, in line with forecasts. U.S. Refreshment Beverages volume grew 5%, and sales rose 10.5%, driven by strong demand for brands like Dr Pepper, Snapple, and its majority-owned Ghost energy drinks. Ghost alone accounted for ~4 points of volume growth. Jonathan Weiss/ Meanwhile, management cautioned about looming 50% tariffs on Brazilian coffee beans starting August 1, 2025, as well as inflation from poor crop weather, which could pressure margins in its coffee segment through year-end, even as prices have already been raised earlier this year. Keurig Dr Pepper, formed in 2018 via merger, encompasses iconic beverages like Dr Pepper, Canada Dry, Snapple, Keurig single‑serve coffee pods, and the fast‑growing Ghost energy brand. While we acknowledge the potential of KDP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
